Cyclic 5-day-on/2-day-off 1mg melatonin protocol maintains MT1/MT2 receptor sensitivity while providing continuous neuroprotection, preventing receptor desensitization observed with continuous high-dose exposure. However, long-term human melatonin receptor studies do not demonstrate clinically significant desensitization—tens of millions of chronic users do not report progressive loss of efficacy. The foundational premise of receptor desensitization in humans is unproven. Cell culture models do not recapitulate receptor turnover dynamics in intact human neural tissue. The 5-on/2-off schedule is arbitrary with no clinical trial evidence. Pulsatile receptor stimulation may actually destabilize circadian rhythms.
Curated pathway from expert analysis
flowchart TD
A["Epigenetic Silencing<br/>REST Convergence Hub Overactivation"]
B["Neuronal Gene Repression<br/>REST Binding to RE1 Elements"]
C["HDAC Recruitment<br/>Histone Deacetylase Co-Repressor Complex"]
D["DNMT Activity<br/>CpG Methylation of Neuronal Promoters"]
E["Neuronal Function Loss<br/>Synaptic Plasticity and Survival Gene Silencing"]
F["Combinatorial HDAC/DNMT Inhibition<br/>Vorinostat plus Azacytidine"]
A --> B
B --> C
B --> D
C --> E
D --> E
F -.->|"relieves"| C
F -.->|"relieves"| D
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style E fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style F fill:#1b5e20,stroke:#81c784,color:#81c784No linked papers recorded for this hypothesis yet.
No curated PDB or AlphaFold mapping for MT1 yet. Search RCSB →
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for MT1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No resource usage or linked notebooks recorded for this hypothesis yet.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF healthy adults (aged 30-55) with chronic insomnia take continuous melatonin (2mg nightly) for 12 weeks, THEN MT1/MT2 receptor sensitivity will decrease by at least 25% as measured by dim-light mela | Significant decrease in receptor sensitivity markers (reduced phase-shift amplitude, decreased sleep efficiency maintenance) indicating functional desensitizati | — no observation — | pending | 0.25 |
| IF older adults (≥65 years) with mild cognitive impairment are randomized to 5-day-on/2-day-off pulsatile melatonin (1mg) versus continuous nightly melatonin (1mg) versus placebo for 6 months, THEN th | Superior neuroprotective effect in pulsatile group (5-on/2-off) with significantly better cognitive outcomes and brain structure preservation | — no observation — | pending | 0.30 |